INVITATION TO PRESENTATION OF FIRST QUARTER 2016 FINANCIAL RESULTS

NattoPharma will release its first quarter 2016 financial results on Friday 20
May 2016 at approximately 08:30 CET. The first quarter 2016 report will be made
available at www.nattopharma.com and at www.oslobors.no.

The same day, starting at 10:00 am, the company will host a webcast with a
presentation of the quarterly results, followed by an online Q&A session.

Please follow the below link to join the web-cast,

http://webtv.hegnar.no/presentation.php?webcastId=33172211

The presentation will be held by CEO Daniel H. Rosenbaum and CFO Kjetil Ramsøy.

For more information, please contact:

Kjetil Ramsøy

CFO, NattoPharma

Mobil: +47 906 12 943

E-mail: kjetil.ramsoy@nattopharma.com

This information is subject to the disclosure requirements pursuant to section 5
-12 of the Norwegian Securities Trading Act.

About NattoPharma and MenaQ7®

NattoPharma ASA, based in Norway, is the world's leader in vitamin K2 R&D.
NattoPharma is the exclusive international supplier of MenaQ7® Vitamin K2 as MK
-7, the best documented, commercially available Vitamin K2 as MK-7 with
guaranteed actives and stability, clinical substantiation, and international
patents granted and pending. The company has a multi-year research and
development program to substantiate and discover the health benefits of vitamin
K2 for applications in the marketplace for functional food and dietary
supplements. With a global presence, the company established its North American
subsidiary, NattoPharma USA, Inc., in Metuchen, NJ.

For more information, visit www.nattopharma.com or www.Menaq7.com